DEA Lightens CBD Research Laws
We all know that the Feds have been a major reason why we've had such difficulties legalizing canna is across the country. Although many states have legalized, they still face the threat of dealing with federal law when it comes to cannabis. That is, at least, until this holiday season.
The DEA announced that reasearchers will no longer have to go an extra mile to request approval for conducting Food and Drug Administration-approved clinical trials on CBD, a marijuana derivitive. They stated, "Prior to now, researchers who expanded the scope of their studies and needed more CBD than they were initially approved for had to request, in writing, a modification to their DEA research registrations – potentially delaying that research while the modification underwent an approval process that includes both the DEA and the FDA. Under these changes, a previously registered CBD clinical researcher who is granted a waiver can readily modify their protocol and continue their research seamlessly. This waiver effectively removes a step from the approval process."
This change could be a big step towards recognizing the medical benefits of cannabis and the possibility of reconsidering the classification of marijuana as a Schedule I drug.